title: Chronic oral etoposide in non-small cell lung carcinoma.
abstract: 25 consecutive inoperable or extended non-small cell lung cancer (NSCLC) patients (19 non-chemotherapy pretreated, 6 non-heavily pretreated) were given oral etoposide, 50 mg/m2/day for 21 successive days, every 4 weeks. 5 partial responses (PR), 9 disease stabilizations were achieved; the overall response rate of 20% (95% confidence interval, 4% to 36%) or 26% in non-pretreated patients. Median survival and PR duration probabilities were 6.7 months and 6.3 months, respectively. Alopecia excepted (96% of patients), non-haematological toxicity was mild. Haematological toxicity WHO grade II+III mainly consisted of leukopenia (28%).
authors.affiliation: Medical Oncology Department, Clinic Hospital, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Estapé
authors.forename: H
authors.initials: H
authors.lastname: Palombo
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Lloret
authors.forename: C
authors.initials: C
authors.lastname: Agustí
authors.forename: J J
authors.initials: JJ
authors.lastname: Grau
authors.forename: M
authors.initials: M
authors.lastname: Daniels
authors.forename: N
authors.initials: N
authors.lastname: Viñolas
authors.forename: C
authors.initials: C
authors.lastname: Solá
authors.forename: A
authors.initials: A
authors.lastname: Biete
authors.forename: J
authors.initials: J
authors.lastname: Ramirez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide